NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Iambic Therapeutics IAM

Iambic Therapeutics listed on Nasdaq on 15 Oct 2026 and is not in the S&P 500. It is worth $698 million. Its price history starts on 16 Oct 2026. Its board is not in our data yet.

Listed
15 Oct 2026 on Nasdaq, IPO filings and terms
Headquarters
San Diego, CA
Market cap
$698M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Sep 2026, from Iambic Therapeutics' quarterly filings.

Quarters since Sep 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Sep 2025 to Sep 2026

Not reported for enough quarters.

Iambic Therapeutics' market cap

Iambic Therapeutics was worth $1.2B at the end of its first week of trading, on 16 Oct 2026, and is worth $698M now.

Board and leadership

Board and officers

Iambic Therapeutics' board is not in our data yet. It listed on 15 Oct 2026 and has not filed a proxy statement. See its 8-K filings.

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $11.5 million in 1 purchase in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
16 Oct 2026BuyEvan Lockwood RachlinDirectorDirectorBuy718,750$12M

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: Iambic Therapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.